Acquiring recognized the palmitoylation motif of APLNR, we designed a short substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This aggressive peptide, which targets the APLNR palmitoylation web-site in combination with morphine, can inhibit the event of NCP, such as pain incidence, microglial activation, and inflammatory factor https://brucen516gvl1.wikissl.com/user